You Li’s team optimized an EGFRvIII-specific CAR construct with the TGFRII ectodomain as a TGFβ-resistant CAR-T for glioblastoma therapy, and the results showed that the architecture enhanced the antitumor efficacy of EGFRvIII-specific CAR-T cells and prolonged the survival of glioblastoma-bearing mice [60]. The gene discussed is TGFB1; the disease is glioblastoma.